We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

174 hedge funds and large institutions have $1.86B invested in Celldex Therapeutics in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 66 increasing their positions, 48 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more call options, than puts

Call options by funds: $24.9M | Put options by funds: $17.1M

38% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 48

2.75% more ownership

Funds ownership: 108.33% → 111.07% (+2.7%)

6% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 36

1% less funds holding

Funds holding: 176 → 174 (-2)

24% less capital invested

Capital invested by funds: $2.44B → $1.86B (-$579M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
174
Holders Change
-2
Holders Change %
-1.14%
% of All Funds
2.29%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
34
Increased
66
Reduced
48
Closed
36
Calls
$24.9M
Puts
$17.1M
Net Calls
+$7.83M
Net Calls Change
-$17.5M

Top Buyers

1
JFG
Jefferies Financial Group
New York
+$64.4M
2
KCM
Kynam Capital Management
New Jersey
+$43.6M
3
DTC
Deep Track Capital
Connecticut
+$41.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$25.7M
5
Morgan Stanley
Morgan Stanley
New York
+$24.7M

Top Sellers

1
CC
Commodore Capital
New York
-$55M
2
Jennison Associates
Jennison Associates
New York
-$45M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$31.7M
4
PCH
Polar Capital Holdings
United Kingdom
-$31.4M
5
LGM
Logos Global Management
California
-$30.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$227M -$7.28M -267,766 -3%
BlackRock
2
BlackRock
New York
$138M +$16.3M +600,650 +12%
KCM
3
Kynam Capital Management
New Jersey
$128M +$43.6M +1,605,598 +46%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$123M -$31.7M -1,166,748 -19%
Vanguard Group
5
Vanguard Group
Pennsylvania
$98.1M +$332K +12,213 +0.3%
EAM
6
Eventide Asset Management
Massachusetts
$94.8M +$11.4M +421,255 +13%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$89.9M +$18.4M +676,771 +23%
State Street
8
State Street
Massachusetts
$81.7M +$20.4M +749,805 +30%
BG
9
Bellevue Group
Switzerland
$77.6M – – –
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$63.6M +$25.7M +947,264 +60%
JFG
11
Jefferies Financial Group
New York
$60.4M +$64.4M +2,369,398 +11,283%
WP
12
Woodline Partners
California
$50.9M -$8.89M -327,106 -14%
T. Rowe Price Investment Management
13
T. Rowe Price Investment Management
Maryland
$42.9M -$1.01M -37,024 -2%
PCH
14
Polar Capital Holdings
United Kingdom
$39.6M -$31.4M -1,155,046 -42%
DTC
15
Deep Track Capital
Connecticut
$38.9M +$41.8M +1,540,132 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$38.8M -$152K -5,597 -0.4%
Morgan Stanley
17
Morgan Stanley
New York
$34M +$24.7M +908,281 +208%
RSCM
18
Rock Springs Capital Management
Maryland
$30.9M +$3.22M +118,404 +11%
Goldman Sachs
19
Goldman Sachs
New York
$30.4M -$17.2M -633,390 -35%
Pictet Asset Management
20
Pictet Asset Management
Switzerland
$27.5M -$1.31M -48,273 -4%
NHAS
21
Novo Holdings A/S
Denmark
$25.3M +$987K +36,337 +4%
EP
22
Eversept Partners
New York
$18.2M +$4.21M +154,934 +27%
Citadel Advisors
23
Citadel Advisors
Florida
$17.9M -$3.78M -139,195 -16%
RG
24
Redmile Group
California
$15.6M -$1.12M -41,400 -6%
American Century Companies
25
American Century Companies
Missouri
$15.4M +$5.25M +193,093 +46%
1
2 3 4 5

CLDX Hedge Fund Activity: Q4 2024 in Review

174 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2024, worth a combined $1.86B — down 24% from $2.44B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CLDX and 34 opened new positions — a net loss of 2 holders — while 48 trimmed existing stakes and 66 added.

The largest buyer was Jefferies Financial Group, adding an estimated $64.4M. The largest seller was Commodore Capital, exiting entirely with an estimated $55M sold.

  • 174 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2024, down from 176 in Q3 2024.
  • Funds reported $1.86B of Celldex Therapeutics stock for Q4 2024, down 24% quarter-over-quarter.
  • 34 funds opened new Celldex Therapeutics positions in Q4 2024 and 36 closed out, a net change of -2 holders.
  • The largest Celldex Therapeutics buyer in Q4 2024 was Jefferies Financial Group, an estimated $64.4M added.
  • The largest Celldex Therapeutics seller in Q4 2024 was Commodore Capital, an estimated $55M sold.

Based on aggregated 13F filings for Q4 2024.